Area of focus

Post-Grant Proceedings

The U.S. patent landscape has undergone dramatic changes. The America Invents Act empowered petitioners by providing several options for challenging issued patents — inter partes review (IPR), covered business method review (CBM), and post-grant review (PGR). Both petitioners and patent owners need to know how and...

Representative experience

Represented Amgen in inter partes review proceeding relating to patents covering chemotherapy products. We successfully preserved a commercially valuable patent claim. Appeal pending.

Represented Leachman Cattle in the very first post-grant proceeding through to oral arguments, in which we successfully knocked out all prior art invalidity grounds.

Represented Mercedes-Benz in connection with multiple inter partes review proceedings, including implementing novel approaches to coordinate IPR strategy with reexamination strategy.

Represented Sandbox Logistics in a a derivation proceeding before the USPTO to challenge a competitor’s patent application. This derivation proceeding was only the seventh.

Represented Merck in inter partes review proceedings challenging the validity of the world’s top selling vaccine patent; after oral argument and written decision, we invalidated 21 patent claims.

Leveraged the filing of five IPRs for Ricoh at a strategic time in corresponding district court litigation, causing patent owner Round Rock Research to settle the litigation on favorable terms for our client.

Represented Depomed in IPR proceedings before the PTAB upholding the validity of all challenged claims. This representation was one the first instances of a generic pharmaceutical company seeking IPR actions.

Represented Depomed in IPR proceedings before the PTAB upholding the validity of all challenged claims. This representation was one the first instances of a generic pharmaceutical company seeking IPR actions.

Loading data